Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathee Till

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Archives of Osteoporosis|July 29, 2019
Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claimsAfsaneh Barzi, Dawn L Hershman, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 22, 2011
Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention TrialAlan R Kristal, Cathee Till, Elizabeth A Platz, et al.
European Urology Focus|March 21, 2026
Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein ModelEmily A Vertosick, Phyllis Goodman, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 14, 2015
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialSarah H Nash, Cathee Till, Xiaoling Song, et al.
International Journal of Cancer|January 1, 2009
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, John F Alderete, Cathee Till, et al.
Journal of the National Cancer Institute|March 14, 2018
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention TrialJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
Endocrine-Related Cancer|December 10, 2021
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trialCindy H Chau, Cathee Till, Douglas K Price, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 25, 2010
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention TrialMarian L Neuhouser, Cathee Till, Alan Kristal, et al.
American Journal of Epidemiology|April 27, 2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialTheodore M Brasky, Cathee Till, Emily White, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Archives of Osteoporosis|July 29, 2019
Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claimsAfsaneh Barzi, Dawn L Hershman, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 22, 2011
Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention TrialAlan R Kristal, Cathee Till, Elizabeth A Platz, et al.
European Urology Focus|March 21, 2026
Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein ModelEmily A Vertosick, Phyllis Goodman, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 14, 2015
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialSarah H Nash, Cathee Till, Xiaoling Song, et al.
International Journal of Cancer|January 1, 2009
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, John F Alderete, Cathee Till, et al.
Journal of the National Cancer Institute|March 14, 2018
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention TrialJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
Endocrine-Related Cancer|December 10, 2021
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trialCindy H Chau, Cathee Till, Douglas K Price, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 25, 2010
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention TrialMarian L Neuhouser, Cathee Till, Alan Kristal, et al.
American Journal of Epidemiology|April 27, 2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialTheodore M Brasky, Cathee Till, Emily White, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Pageof 7